NIH Weekly Funding Opportunities and Policy Notices
Notice NOT-OD-22-190 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-DA-23-054 from the NIH Guide for Grants and Contracts. This RFA will act as a parent RFA for the HEAL initiative Translation to Practice Team, specifically encouraging translational dissemination and implementation research focused on addressing overdose deaths and the intersection of pain and OUD. This RFA will function in tandem with targeted NOSIs that announce more specific areas of focus. For FY23, this currently includes the Workforce NOSI (formerly an RFA) and the Violence and Trauma NOSI (also formerly an RFA). It has a companion R61/R33 RFA and is expected to run for 2 years (FY23 and FY24)
Funding Opportunity RFA-DA-23-053 from the NIH Guide for Grants and Contracts. This RFA will act as a parent RFA for the HEAL initiative Translation to Practice Team, specifically encouraging translational dissemination and implementation research focused on addressing overdose deaths and the intersection of pain and OUD. This RFA will function in tandem with targeted NOSIs that announce more specific areas of focus. For FY23, this currently includes the Workforce NOSI (formerly an RFA) and the Violence and Trauma NOSI (also formerly an RFA). It has a companion R33 RFA and is expected to run for 2 years (FY23 and FY24).
Notice NOT-NS-23-002 from the NIH Guide for Grants and Contracts
Notice NOT-DA-23-007 from the NIH Guide for Grants and Contracts
Notice NOT-DA-23-008 from the NIH Guide for Grants and Contracts
Notice NOT-CA-22-091 from the NIH Guide for Grants and Contracts
Notice NOT-NS-23-020 from the NIH Guide for Grants and Contracts
Notice NOT-CA-22-116 from the NIH Guide for Grants and Contracts
Notice NOT-GM-22-042 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-CA-22-019 from the NIH Guide for Grants and Contracts. The purpose of the Global Implementation Science for Equitable Cancer Control (GlobalISE Cancer Control) Funding Opportunity Announcement (FOA) is to build implementation science centers in low- and middle-income countries (LMICs). This initiative will support implementation science research capacity-building activities, including research projects that identify, develop, and test innovative theory-based strategies for overcoming barriers to the adoption, adaptation, integration, scale-up, and sustainability of evidence-based cancer control interventions (e.g., programs, tools, policies, and guidelines) in LMICs. NCI will support several U54 Specialized Centers with transdisciplinary research teams meaningfully collaborating with key stakeholders (e.g., health systems, ministries of health, clinicians, and communities) that must include at least one PI or MPI from an LMIC-based institution. This initiative aims to foster LMIC-based implementation science programs to inform implementation of cancer control efforts in LMICs.
Funding Opportunity RFA-NS-22-059 from the NIH Guide for Grants and Contracts. This funding opportunity announcement (FOA) encourages early-stage development of novel small molecule or biologic therapeutics for NINDS mission-relevant? Alzheimer's and related dementias: frontotemporal degeneration (FTD, including Picks disease and progressive supranuclear palsy), Lewy body dementias (LBD; including dementia with Lewy bodies (DLB) and Parkinsons disease dementia (PDD), vascular contributions to cognitive impairment and dementia (VCID), and multiple etiology dementias (MED). This FOA covers four stages of early therapy discovery/development with each stage gated by go/no-go milestones. Applicants may enter the program at the stage appropriate to their research. The R61 phase supports preparatory research stages 1 -3: 1) development of in vitro and/or ex vivo assays that can support therapeutic screening efforts, 2) screening efforts to identify and characterize potential therapeutic agents, and 3) therapeutic optimization, pharmacodynamic and pharmacokinetic studies. The R33 phase supports stage 4, in vivo efficacy studies in an animal model of disease. This FOA supports research to enable competitive follow-on applications that meet the entry criteria for the Blueprint Neurotherapeutics Network, Blueprint Biologics, or other similar later-stage translational programs.
Funding Opportunity RFA-DE-23-006 from the NIH Guide for Grants and Contracts. The goal of this FOA is to solicit applications to accelerate development, testing and implementation of advanced data-driven tools specifically designed to overcome critical problems affecting research and development (R and D) cycles that might contribute to delays in regulatory approval and human use of novel biomaterials for dental, oral, and craniofacial (DOC) applications. It is part of a suite of FOAs that encourage applicants to leverage the FDA-CDRHs Medical Device Development Tools (MDDT) Program framework as an innovative and important pathway to ensure that outcomes of funded studies yield practical and validated tools that are qualified by FDA to support a particular context-of-use. The overall objectives are to: 1) accelerate R and D cycles of biomaterials for DOC applications by de-risking potential safety and effectiveness uncertainties through robust and predictive preclinical characterization; 2) support technical developments and validation activities needed to satisfy the FDA MDDT qualification process for proposed data-driven tools; 3) promote multi-domain collaborations and empower workforce development at the intersection of data-driven technologies and biomaterial science in dentistry; and 4) build confidence in the use of data-driven technologies in biomaterials innovation by establishing pipelines of robust and validated tools that are qualified by FDA.
Funding Opportunity RFA-DE-23-007 from the NIH Guide for Grants and Contracts. The goal of this FOA is to solicit applications to accelerate development, testing and implementation of advanced data-driven tools specifically designed to overcome critical problems affecting research and development (R and D) cycles that might contribute to delays in regulatory approval and human use of novel biomaterials for dental, oral, and craniofacial (DOC) applications. It is part of a suite of FOAs that encourage applicants to leverage the FDA-CDRHs Medical Device Development Tools (MDDT) Program framework as an innovative and important pathway to ensure that outcomes of funded studies yield practical and validated tools that are qualified by FDA to support a particular context-of-use. The overall objectives are to: 1) accelerate R and D cycles of biomaterials for DOC applications by de-risking potential safety and effectiveness uncertainties through robust and predictive preclinical characterization; 2) support technical developments and validation activities needed to satisfy the FDA MDDT qualification process for proposed data-driven tools; 3) promote multi-domain collaborations and empower workforce development at the intersection of data-driven technologies and biomaterial science in dentistry; and 4) build confidence in the use of data-driven technologies in biomaterials innovation by establishing pipelines of robust and validated tools that are qualified by FDA.
Funding Opportunity RFA-DE-23-008 from the NIH Guide for Grants and Contracts. The goal of this FOA is to solicit applications to accelerate development, testing and implementation of advanced data-driven tools specifically designed to overcome critical problems affecting research and development (R and D) cycles that might contribute to delays in regulatory approval and human use of novel biomaterials for dental, oral, and craniofacial (DOC) applications. It is part of a suite of FOAs that encourage applicants to leverage the FDA-CDRHs Medical Device Development Tools (MDDT) Program framework as an innovative and important pathway to ensure that outcomes of funded studies yield practical and validated tools that are qualified by FDA to support a particular context-of-use. The overall objectives are to: 1) accelerate R and D cycles of biomaterials for DOC applications by de-risking potential safety and effectiveness uncertainties through robust and predictive preclinical characterization; 2) support technical developments and validation activities needed to satisfy the FDA MDDT qualification process for proposed data-driven tools; 3) promote multi-domain collaborations and empower workforce development at the intersection of data-driven technologies and biomaterial science in dentistry; and 4) build confidence in the use of data-driven technologies in biomaterials innovation by establishing pipelines of robust and validated tools that are qualified by FDA.
Notice NOT-CA-22-114 from the NIH Guide for Grants and Contracts
Notice NOT-HD-22-032 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-HD-23-029 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity announcement (FOA) is to support and facilitate multidisciplinary approaches towards the development of new and/or improved contraceptive methods for both men and women through the formation of a Contraceptive Development Research Center. This FOA also allows the inclusion of translational studies to facilitate the pre-clinical to clinical transition and increase the likelihood of clinical success. The Center will serve as a national resource for development of early stage investigators electing to pursue careers in contraceptive research.
Funding Opportunity RFA-NS-23-003 from the NIH Guide for Grants and Contracts. More than 25 million Americans suffer from daily chronic pain, a highly debilitating medical condition that is complex and difficult to manage. In recent decades, there has been an overreliance in the prescription of opioids for chronic pain despite their poor ability to improve function and high addiction liability. This contributed to a significant and alarming epidemic of opioid overdose deaths and addictions. Innovative scientific solutions to develop alternative pain treatment options are thus critically needed. Through targeted research efforts, the NIH HEAL Initiative aims to support the development of safe and effective devices to treat pain with little or no addiction liability. This funding opportunity announcement (FOA) is designed to support interdisciplinary research teams of multiple PD/PIs to investigate the mechanism of action of pain relief by medical devices with the overall goal of optimizing therapeutic outcomes for FDA-approved or -cleared technologies. Program teams are expected to accomplish goals that require considerable synergy and collaborative interactions. Teams must leverage appropriate multi-disciplinary expertise to develop new principles and methods for experimentation, analysis, and interpretation. Teams are encouraged to consider objectives that will produce major advances in the field of pain relief by medical devices.
Funding Opportunity PAR-22-220 from the NIH Guide for Grants and Contracts. This funding opportunity announcement (FOA) provides support to eligible, domestic institutions to develop and implement effective, evidence-informed approaches to biomedical research education and mentoring that will keep pace with the rapid evolution of the research enterprise. NIGMS expects that the proposed research education programs will incorporate extensive research experiences, well-designed courses for skills development, mentoring, cohort building activities, and career development elements to prepare recent baccalaureates from diverse backgrounds to transition into and complete rigorous research-focused doctoral degree programs (e.g., Ph.D. or M.D./Ph.D.) in biomedical fields. This program is limited to applications from doctoral degree-granting research-intensive institutions.This Funding Opportunity Announcement (FOA) does not allow appointed participants to lead an independent clinical trial but does allow them to obtain research experience in a clinical trial led by a mentor or co-mentor.